Lumexa Imaging (NASDAQ:LMRI) Stock Jumps 12.2% – What’s Next?

Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI)’s share price traded up 12.2% on Wednesday. The stock traded as high as $12.29 and last traded at $12.5850. Approximately 281,442 shares traded hands during mid-day trading, a decline of 59% from the average daily volume of 678,442 shares. The stock had previously closed at $11.22.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LMRI. Truist Financial initiated coverage on Lumexa Imaging in a research note on Monday, October 5th. They set a “buy” rating and a $18.00 price objective for the company. Barclays increased their target price on Lumexa Imaging from $9.00 to $13.00 and gave the stock an “overweight” rating in a research note on Friday, August 28th. Deutsche Bank Aktiengesellschaft set a $16.00 price target on Lumexa Imaging in a report on Thursday, August 13th. Wall Street Zen raised Lumexa Imaging from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Finally, UBS Group reiterated a “strong-buy” rating on shares of Lumexa Imaging in a research note on Monday, September 28th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Lumexa Imaging presently has an average rating of “Buy” and an average target price of $16.40.

Lumexa Imaging Trading Up 14.9%

The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.44 and a current ratio of 1.44. The firm has a market cap of $1.24 billion and a PE ratio of -26.39. The stock has a 50-day simple moving average of $11.07 and a two-hundred day simple moving average of $11.11.

Lumexa Imaging (NASDAQ:LMRI) last announced its quarterly earnings results on Wednesday, August 12th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.17. The company had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. As a group, sell-side analysts anticipate that Lumexa Imaging Holdings, Inc. will post 0.25 EPS for the current year.

Institutional Investors Weigh In On Lumexa Imaging

Large investors have recently added to or reduced their stakes in the stock. State of Wyoming bought a new position in shares of Lumexa Imaging during the 3rd quarter valued at $132,000. Brooklands Fund Management Ltd purchased a new position in shares of Lumexa Imaging in the 3rd quarter worth $21,577,000. State of Alaska Department of Revenue bought a new stake in shares of Lumexa Imaging in the third quarter worth $46,000. Squarepoint Ops LLC grew its holdings in shares of Lumexa Imaging by 506.9% in the second quarter. Squarepoint Ops LLC now owns 79,934 shares of the company’s stock worth $902,000 after acquiring an additional 66,763 shares during the period. Finally, Readystate Asset Management LP increased its position in Lumexa Imaging by 11.5% during the second quarter. Readystate Asset Management LP now owns 250,533 shares of the company’s stock valued at $2,826,000 after acquiring an additional 25,778 shares during the last quarter.

About Lumexa Imaging

Lumexa Imaging is a U.S.-based provider of outpatient diagnostic imaging and radiology services. The company operates imaging centers and offers services designed to support physicians, hospitals, health systems and patients in the diagnosis and monitoring of medical conditions.

Its service portfolio includes advanced imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound and X-ray. Lumexa also provides radiology-related services, including image interpretation and support for referring healthcare providers, through fixed-site and mobile imaging operations.

The company serves communities across the United States through its network of outpatient facilities and healthcare partnerships.